المؤلفون: Leng X; Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China., Leszczyński P; Department of Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland., Jeka S; Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2, CM UMK, Bydgoszcz, Poland., Liu S; First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu H; Qilu Hospital of Shandong University, Jinan, China., Miakisz M; Twoja Przychodnia Centrum Medyczne, Nowa Sól, Poland., Gu J; The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Kilasonia L; Tbilisi Heart and Vascular Clinic Ltd, Tbilisi, Georgia., Stanislavchuk M; National Pirogov Memorial Medical University, Vinnytsia, Ukraine., Yang X; Bio-Thera Solutions Ltd, Guangzhou, China., Zhou Y; Bio-Thera Solutions Ltd, Guangzhou, China., Dong Q; Bio-Thera Solutions Ltd, Guangzhou, China., Mitroiu M; Biogen International GmbH, Baar, Switzerland., Addison J; Biogen Idec Ltd, Maidenhead, UK., Rezk MF; Biogen International GmbH, Baar, Switzerland., Zeng X; Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China. zengxfpumc@163.com.

المصدر: Arthritis research & therapy [Arthritis Res Ther] 2024 Sep 07; Vol. 26 (1), pp. 157. Date of Electronic Publication: 2024 Sep 07.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE

مواضيع طبية MeSH: Arthritis, Rheumatoid*/drug therapy , Methotrexate*/therapeutic use , Methotrexate*/pharmacokinetics , Methotrexate*/administration & dosage , Biosimilar Pharmaceuticals*/pharmacokinetics , Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/administration & dosage , Biosimilar Pharmaceuticals*/adverse effects , Antirheumatic Agents*/pharmacokinetics , Antirheumatic Agents*/therapeutic use , Antirheumatic Agents*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects, Humans ; Male ; Female ; Double-Blind Method ; Middle Aged ; Adult ; Treatment Outcome ; Aged ; Severity of Illness Index

المؤلفون: Cageling R; Analytical Development, Polpharma Biologics, Yalelaan 46, Utrecht, 3584 CM, the Netherlands; Division of BioAnalytical Chemistry, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, de Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands; Centre for Analytical Sciences Amsterdam (CASA), Amsterdam, the Netherlands., Carillo S; National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, A94 X099, Ireland., Boumeester AJ; Analytical Development, Polpharma Biologics, Yalelaan 46, Utrecht, 3584 CM, the Netherlands., Lubbers-Geuijen K; Analytical Development, Polpharma Biologics, Yalelaan 46, Utrecht, 3584 CM, the Netherlands., Bones J; National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, A94 X099, Ireland; School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland., Jooß K; Division of BioAnalytical Chemistry, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, de Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands; Centre for Analytical Sciences Amsterdam (CASA), Amsterdam, the Netherlands. Electronic address: k.jooss@vu.nl., Somsen GW; Division of BioAnalytical Chemistry, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, de Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands; Centre for Analytical Sciences Amsterdam (CASA), Amsterdam, the Netherlands.

المصدر: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Sep 15; Vol. 248, pp. 116301. Date of Electronic Publication: 2024 Jun 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE

مواضيع طبية MeSH: Biosimilar Pharmaceuticals*/analysis , Biosimilar Pharmaceuticals*/chemistry , Antibodies, Monoclonal*/chemistry , Antibodies, Monoclonal*/analysis , Electrophoresis, Capillary*/methods , Mass Spectrometry*/methods, Cricetulus ; CHO Cells ; Animals ; Humans ; Glycosylation

المؤلفون: Tomaszewska-Kiecana M; Biokinetica S.A., Józefów, Poland., Carapuça E; Medical Department, mAbxience Research S.L.U., Madrid, Spain., Florez-Igual A; Medical Department, mAbxience Research S.L.U., Madrid, Spain., Queiruga-Parada J; Medical Department, mAbxience Research S.L.U., Madrid, Spain.

المصدر: Clinical and translational science [Clin Transl Sci] 2024 Sep; Vol. 17 (9), pp. e70013.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial

بيانات الدورية: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/pharmacokinetics , Denosumab*/administration & dosage , Denosumab*/adverse effects , Biosimilar Pharmaceuticals*/pharmacokinetics , Biosimilar Pharmaceuticals*/administration & dosage , Biosimilar Pharmaceuticals*/adverse effects , Healthy Volunteers*, Humans ; Male ; Adult ; Double-Blind Method ; Middle Aged ; Young Adult ; Area Under Curve ; Bone Density Conservation Agents/pharmacokinetics ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/adverse effects ; Therapeutic Equivalency ; Adolescent ; Injections, Subcutaneous ; Half-Life

المؤلفون: Martínez-Vidal MP; M.P. Martínez-Vidal, MD, PhD, C. Fernández-Carballido, MD, PhD, Hospital Universitario San Juan de Alicante, Alicante; Mpmavidal@yahoo.es., Fernández-Carballido C; M.P. Martínez-Vidal, MD, PhD, C. Fernández-Carballido, MD, PhD, Hospital Universitario San Juan de Alicante, Alicante., Otero-Varela L; L. Otero-Varela, MSc, F. Sánchez-Alonso, MSc, Unidad de Investigación Sociedad Española de Reumatología, Madrid., Ruiz FJM; F.J. Manero Ruiz, MD, PhD, Hospital Universitario Miguel Servet, Zaragoza., Pérez-Vera Y; Y. Pérez-Vera, MD, Hospital Universitario Dr. Negrín, Gran Canaria., Arija SM; S. Manrique Arija, MD, Hospital Regional Universitario de Málaga, Málaga., Fernández CC; C. Campos Fernández, MD, Hospital General Universitario de Valencia, Valencia., Jovaní V; V. Jovaní, MD, PhD, Hospital General Universitario Dr. Balmis, Alicante., Expósito L; L. Expósito, MD, Hospital Universitario de Canarias, Santa Cruz de Tenerife., Lario BÁ; B. Álvarez Lario, MD, Hospital Universitario de Burgos, Burgos., García-González J; J. García-González, MD, Hospital Universitario 12 de Octubre, Madrid., Sánchez-Alonso F; L. Otero-Varela, MSc, F. Sánchez-Alonso, MSc, Unidad de Investigación Sociedad Española de Reumatología, Madrid., Castrejón I; I. Castrejón, MD, PhD, Hospital Universitario Gregorio Marañón, Madrid, Spain.

المصدر: The Journal of rheumatology [J Rheumatol] 2024 Sep 01; Vol. 51 (9), pp. 877-883. Date of Electronic Publication: 2024 Sep 01.

نوع المنشور: Journal Article; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: Journal Of Rheumatology Publishing Co Country of Publication: Canada NLM ID: 7501984 Publication Model: Electronic Cited Medium: Internet ISSN: 1499-2752 (Electronic) Linking ISSN: 0315162X NLM ISO Abbreviation: J Rheumatol Subsets: MEDLINE

مواضيع طبية MeSH: Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/administration & dosage , Registries* , Antirheumatic Agents*/therapeutic use , Antirheumatic Agents*/administration & dosage , Antirheumatic Agents*/adverse effects , Adalimumab*/therapeutic use , Adalimumab*/administration & dosage , Adalimumab*/adverse effects , Etanercept*/therapeutic use , Etanercept*/administration & dosage , Rheumatic Diseases*/drug therapy , Rheumatic Diseases*/mortality, Humans ; Female ; Male ; Middle Aged ; Adult ; Aged ; Retrospective Studies ; Prospective Studies ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor Inhibitors/adverse effects ; Treatment Outcome ; Injections, Subcutaneous ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Spain/epidemiology

المؤلفون: Christofides EA; Endocrinology Research Associates, Columbus. Electronic address: christofides@endocrinology-associates.com., Stankiewicz A; NZOZ Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne 'Diab-Endo-Met', Kraków, Poland., Denham D; Clinical Trials of Texas, San Antonio., Bellido D; Complejo Hospitalario Universitario de Ferrol, Servicio Endocrinología y Nutricion, Ferrol, Spain., Franek E; Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie, Centrum Diabetologiczne, Klinika Endokrynologii i Diabetologii, Warszawa, Poland., Nakhle S; Palm Research Center, Las Vegas., Łukaszewicz M; Centrum Badań Klinicznych PI-House, Gdańsk, Poland., Reed J; Endocrine Research Solutions, Roswell., Cózar-León V; Hospital Universitario Nuestra Señora de Valme, Universidad de Sevilla, Servicio de Endocrinología y Nutrición, Sevilla, Spain., Kosch C; Diabetologische Schwerpunktpraxis Pirna, Pirna, Germany., Karaś P; KO-MED Centra Kliniczne Lublin, Lublin, Poland., Fitz-Patrick D; East West Medical Research Institute, Honolulu., Handelsman Y; Metabolic Institute of America, Tarzana., Warren M; Physicians East - Greenville, Endocrinology and Metabolism, Greenville., Hollander P; Baylor Endocrine Center, Dallas., Huffman D; University Diabetes & Endocrine Consultants, Chattanooga., Raskin P; Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas., Oroszlán T; Zala County Hospital, Zalaegerszeg, Hungary., Lillestol M; Lillestol Research, Fargo., Ovalle F; Department of Medicine, University of Alabama at Birmingham, Birmingham.

المصدر: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2024 Sep; Vol. 30 (9), pp. 810-816. Date of Electronic Publication: 2024 Jun 12.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Comparative Study; Equivalence Trial

بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9607439 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1530-891X (Print) Linking ISSN: 1530891X NLM ISO Abbreviation: Endocr Pract Subsets: MEDLINE

مواضيع طبية MeSH: Insulin Glargine*/therapeutic use , Insulin Glargine*/adverse effects , Diabetes Mellitus, Type 1*/drug therapy , Diabetes Mellitus, Type 1*/immunology , Diabetes Mellitus, Type 1*/blood , Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/adverse effects , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/adverse effects, Humans ; Male ; Female ; Adult ; Middle Aged ; Glycated Hemoglobin/analysis ; Insulin Antibodies/blood ; Insulin Antibodies/immunology ; Young Adult ; Treatment Outcome ; Adolescent ; Hypoglycemia/chemically induced ; Hypoglycemia/immunology

المؤلفون: Zuo W; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China., Wang Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China., Qian J; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China., Ma X; Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, 230001, China., Niu Z; Department of Breast Disease, Yuncheng Central Hospital, Yuncheng, 044099, China., Ou J; Department of Breast Surgery, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, 830000, China., Mo Q; Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, China., Sun J; The Fifth Department of Internal Medicine, Anyang Tumor Hospital, Anyang, 455000, China., Li X; Department of Breast Surgery, Shanxi Cancer Hospital, Xi'an, 710061, China., Wang Q; Breast Medical Center, Qingdao Central Hospital, Qingdao, 266042, China., Yao Y; Department of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China., Yu G; Department of Oncology, Weifang People's Hospital, Weifang, 261071, China., Li H; Department of Breast Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, 511436, Guangzhou, China., Chen D; The Second Department of Breast surgery, Yunnan Cancer Hospital, Kunming, 650118, China., Zhang H; Department of Breast Surgery, Nanyang Central Hospital, Nanyang, 473005, China., Geng C; Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China., Qiao G; Department of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, 264099, China., Zhao M; Clinical Research Center, Qilu Pharmaceutical Co., Ltd, Jinan, 250105, China., Zhang B; Clinical Research Center, Qilu Pharmaceutical Co., Ltd, Jinan, 250105, China., Kang X; Clinical Research Center, Qilu Pharmaceutical Co., Ltd, Jinan, 250105, China., Zhang J; The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China. zhangjintjmuch1@163.com., Shao Z; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. zhimingshao@fudan.edu.cn.

المصدر: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (4), pp. 668-675. Date of Electronic Publication: 2024 Jun 21.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Trastuzumab*/administration & dosage , Trastuzumab*/therapeutic use , Neoadjuvant Therapy* , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Docetaxel*/administration & dosage , Receptor, ErbB-2*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Biosimilar Pharmaceuticals*/administration & dosage , Biosimilar Pharmaceuticals*/therapeutic use, Humans ; Female ; Middle Aged ; Double-Blind Method ; Adult ; Aged ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism

المؤلفون: Lee H; Samsung Bioepis, Co., Ltd, Incheon, Republic of Korea., Park J; Samsung Bioepis, Co., Ltd, Incheon, Republic of Korea., Jang H; Samsung Bioepis, Co., Ltd, Incheon, Republic of Korea., Lee SJ; AIMS BioScience, Seoul, Republic of Korea., Kim J; Samsung Medical Center, Seoul, Republic of Korea. jungryul.kim@samsung.com.

المصدر: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Sep; Vol. 80 (9), pp. 1325-1338. Date of Electronic Publication: 2024 May 30.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Models, Biological* , Biosimilar Pharmaceuticals*/pharmacokinetics , Biosimilar Pharmaceuticals*/pharmacology, Humans ; Adult ; Male ; Female ; Middle Aged ; Young Adult ; Hemoglobinuria, Paroxysmal/drug therapy ; Adolescent ; Aged

المؤلفون: Feldman SR; Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, North Carolina. Electronic address: sfeldman@wakehealth.edu., Narbutt J; Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. Lesiak, Łódź, Poland., Girolomoni G; Division of Dermatology, Department of Medicine, University of Verona, Verona, Italy., Brzezicki J; Centrum Kliniczno-Badawcze J.Brzezicki, B.Górnikiewicz-Brzezicka, Lekarze Spółka Partnerska, Elbląg, Poland., Reznichenko N; Therapeutic Department, Military Hospital (Military Unit A3309) of Military Medical Clinical Center of Eastern Region, Zaporizhzhia, Ukraine., Zegadło-Mylik MA; ETG WARSZAWA, Warsaw, Poland., Pulka G; Centrum Medyczne All-med BADANIA KLINICZNE, Kraków, Poland., Dmowska-Stecewicz M; ETG Siedlce, Siedlce, Poland., Kłujszo E; Prywatny Gabinet Dermatologiczny Elżbieta Kłujszo, Kielce, Poland., Rekalov D; Medical Center of LLC 'Suchasna klinika', Zaporizhzhia, Ukraine., Rajzer L; L.Rajzer Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, Kraków, Poland., Lee J; Samsung Bioepis, Co. Ltd, Incheon, South Korea., Lee M; Samsung Bioepis, Co. Ltd, Incheon, South Korea., Rho YH; Samsung Bioepis, Co. Ltd, Incheon, South Korea.

المصدر: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep; Vol. 91 (3), pp. 440-447. Date of Electronic Publication: 2024 Apr 27.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Psoriasis*/drug therapy , Ustekinumab*/therapeutic use , Ustekinumab*/administration & dosage , Ustekinumab*/adverse effects , Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/adverse effects , Biosimilar Pharmaceuticals*/administration & dosage , Severity of Illness Index*, Humans ; Double-Blind Method ; Male ; Female ; Middle Aged ; Adult ; Dermatologic Agents/therapeutic use ; Dermatologic Agents/adverse effects ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/pharmacokinetics ; Treatment Outcome ; Therapeutic Equivalency ; Injections, Subcutaneous

المؤلفون: Yao F; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Wang C; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Ding J; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Zhang Q; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Zheng L; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Zhang Q; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Yang T; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Zhang X; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Shan Y; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Hou S; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Wang H; Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China., Zhou R; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China., Hu W; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2024 Aug 29; Vol. 18, pp. 3891-3901. Date of Electronic Publication: 2024 Aug 29 (Print Publication: 2024).

نوع المنشور: Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/adverse effects , Biosimilar Pharmaceuticals*/adverse effects , Biosimilar Pharmaceuticals*/pharmacokinetics , Healthy Volunteers*, Adult ; Humans ; Male ; Middle Aged ; Young Adult ; China ; Double-Blind Method ; East Asian People ; Therapeutic Equivalency

المؤلفون: Niazi SK; College of Pharmacy, University of Illinois, Chicago, IL 60612, USA., Omarsdottir S; Faculty of Pharmaceutical Sciences, University of Iceland, IS-107 Reykjavik, Iceland.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 26; Vol. 25 (17). Date of Electronic Publication: 2024 Aug 26.

نوع المنشور: Journal Article; Comparative Study; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Lectins*/metabolism , Lectins*/chemistry , Polysaccharides*/chemistry , Polysaccharides*/analysis , Biosimilar Pharmaceuticals*/analysis , Biosimilar Pharmaceuticals*/chemistry, Humans ; United States ; United States Food and Drug Administration ; Glycoproteins/chemistry ; Glycoproteins/analysis ; Drug Approval ; Fluorescence ; Animals